Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse exists. Here we report the rational design and optimization of bispecific CAR-T cells with robust activity against heterogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zah, Eugenia, Nam, Eunwoo, Bhuvan, Vinya, Tran, Uyen, Ji, Brenda Y., Gosliner, Stanley B., Wang, Xiuli, Brown, Christine E., Chen, Yvonne Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210316/
https://www.ncbi.nlm.nih.gov/pubmed/32385241
http://dx.doi.org/10.1038/s41467-020-16160-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210316/
https://www.ncbi.nlm.nih.gov/pubmed/32385241
http://dx.doi.org/10.1038/s41467-020-16160-5

Ejemplares similares